EGFR-TRACTr (JANX008)
JANX008 is currently in a Phase 1 clinical trial for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer.
Epidermal growth factor receptor (EGFR) is a clinically validated target highly expressed on many solid tumors that are being underserved by current therapies. JANX008 is an EGFR-TRACTr that is designed to overcome CRS and known on-target EGFR healthy tissue toxicities.
We designed our EGFR-TRACTr product candidate as a double-masked TRACTr in which the EGFR-binding domain and the T cell-specific binding domain (CD3e) is masked.
In preclinical studies, JANX008 demonstrated potent cleavage dependent anti-tumor activity and was well tolerated in non-human primates, with limited healthy tissue toxicities or CRS. Additionally, JANX008 exhibited enhanced safety and PK properties relative to unmasked TCEs.